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Abstract
Diabetes severity may influence breast cancer treatment choices. We examined whether receipt of 
guideline-concordant breast cancer treatment varied with diabetes severity. Cancer registry data 
from seven states regarding 6,912 stage I–III breast cancers were supplemented by medical record 
abstraction and physician verification. We used logistic regression models to examine associations 
of diabetes severity with guideline-concordant locoregional treatment, adjuvant chemotherapy, and 
hormonal therapy adjusted for sociodemographics, comorbidity, and tumor characteristics. We 
defined guideline concordance using National Comprehensive Cancer Network guidelines, and 
diabetes and comorbidities using the Adult Comorbidity Evaluation-27 index. After adjustment, 
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there was significant interaction of diabetes severity with age for locoregional treatment (p = 
0.001), with many diabetic women under age 70 less frequently receiving guideline-concordant 
treatment than non-diabetic women. Among similarly aged women, guideline concordance was 
lower for women with mild diabetes in their late fifties through mid-sixties, and with moderate/
severe diabetes in their late forties to early sixties. Among women in their mid-seventies to early 
eighties, moderate/severe diabetes was associated with increased guideline concordance. For 
adjuvant chemotherapy, moderate/severe diabetes was less frequently associated with guideline 
concordance than no diabetes [OR 0.58 (95 % CI 0.36–0.94)]. Diabetes was not associated with 
guideline-concordant hormonal treatment (p = 0.929). Some diabetic women were less likely to 
receive guideline-concordant treatment for stage I–III breast cancer than non-diabetic women. 
Diabetes severity was associated with lower guideline concordance for locoregional treatment 
among middle-aged women, and lower guideline concordance for adjuvant chemotherapy. 
Differences were not explained by comorbidity and may contribute to potentially worse breast 
cancer outcomes.
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Introduction
Breast cancer is the most commonly diagnosed non-skin cancer among U.S. women, with 
more than 200,000 women diagnosed in 2010 [1]. Diabetes afflicts 11.3 % of U.S. adults, 
including 27 % of those aged ≥65 (www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf), and 
rates of diabetes are increasing over time [2]. Diabetes is also common among breast cancer 
patients. In a systematic review, 8–32 % of breast cancer patients had diabetes [3], and 
breast cancer incidence may be higher among women with diabetes [4–8]. Furthermore, 
diabetic women may have lower breast cancer survival and greater breast cancer mortality 
[9–14], raising questions about whether differences in cancer treatment might contribute [10, 
15].
Diabetes may influence breast cancer treatment. First, diabetes may increase tumor 
aggressiveness [4, 15, 16]. Second, diabetes-associated comorbid conditions may affect 
breast cancer treatment. For example, impaired renal, cardiac, or neurologic function in 
diabetic women may alter decisions concerning radiation or chemotherapy in order to 
minimize toxicities to these or other systems. Complications of breast cancer treatment are 
more frequent among diabetic women [10]. Concerns about glucocorticoid use may also 
lead to changes in treatment. An association of diabetes severity with receipt of guideline-
concordant breast cancer care would suggest increased risk for recurrence or poor outcomes 
for some diabetic women and need for additional vigilance.
Two studies that examined the association of diabetes with breast cancer treatment in U.S. 
populations found that diabetic women were less likely to receive chemotherapy, including 
anthracyclines or taxanes [10], and axillary lymph node dissections [17] after adjusting for 
age (and for other sociodemographics in chemotherapy analyses), comorbidity and tumor 
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characteristics, and they were also less likely to get radiation therapy and breast-conserving 
surgery without adjustment in one of the studies [10]. These analyses examined patterns of 
care, and with the exception of the analysis of lymph node dissection, did not necessarily 
examine whether treatment received by each woman was concordant with guidelines from 
expert organizations. Guideline-concordant treatment reflects evidence-based care (http://
www.nccn.org/clinical.asp) likely to influence outcomes [18]. Furthermore, it is currently 
unknown whether breast cancer treatment differs by diabetes severity. The purpose of this 
study was to examine whether diabetes severity influences receipt of guideline-concordant 
locoregional and adjuvant therapies for breast cancer.
Methods
As part of the National Program of Cancer Registries (NPCR) Patterns of Care for Breast 
and Prostate Cancer Study (POCBP), we used data from seven population-based cancer 
registries (Georgia, North Carolina, Kentucky, Louisiana, Wisconsin, Minnesota, and 
California) to identify women diagnosed with breast cancer in 2004. Cases were randomly 
sampled after stratifying by race/ethnicity (all states), Appalachian versus non-Appalachian 
regions (North Carolina, Kentucky), facility type and patient volume (Wisconsin), and 
urban/rural status (Georgia). Cancer registry data were enhanced by medical record 
abstraction of sociodemographic, comorbidity, tumor, and treatment information from 
hospital and non-hospital facilities, and from physicians’ offices when facility information 
was incomplete. Data were merged with Census tract-level information on poverty and 
education from the 2000 Census.
We included 6,912 women diagnosed with stage I–III breast cancer (International 
Classification of Diseases for Oncology third edition C50.0–C50.9) in this study; those with 
prior cancers, sarcoma, fibromyxosarcoma, stromal sarcoma, hemangiosarcoma, 
inflammatory cancer, or diagnosis by autopsy or death certificate only were excluded.
Dependent variables included receipt of guideline-concordant locoregional treatment (breast 
cancer surgery, radiation therapy), adjuvant chemotherapy, and hormonal therapy. Guideline 
concordance was defined by whether the treatment received by each woman was consistent 
with the 2003 National Comprehensive Cancer Network (NCCN) guidelines 
(www.nccn.org). When guidelines indicated that a treatment should be “considered,” the 
treatment was categorized as guideline-concordant regardless of whether received because in 
these cases either treatment or no treatment may be appropriate. We programmed an 
algorithm in SAS to determine guideline concordance for each woman based on tumor 
characteristics and prior treatments.
Guideline-concordant locoregional treatment generally included receiving radiation after 
breast-conserving surgery, or after mastectomy with ≥4 positive axillary nodes, tumor ≥5 
cm, or positive margins (www.nccn.org). Exclusions from treatment analyses are shown in 
Fig. 1. For women with T1N0, T0N1, or T1N1 disease, preoperative chemotherapy (pCTX) 
is not recommended. Because breast-conserving surgery with radiation is a recommended 
option both for women with these TN combinations who did not receive pCTX as well as for 
women with non-locally advanced disease who received pCTX, we considered women in 
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these groups who received pCTX guideline-concordant for locoregional treatment if they 
received breast-conserving surgery with radiation. We excluded women with these TN 
combinations who received pCTX and mastectomy because it was unknown whether 
radiation after mastectomy would have been recommended.
For adjuvant chemotherapy, NCCN guidelines indicate that for women over age 70 years 
evidence for chemotherapy is insufficient and treatment should be individualized 
considering comorbid conditions (www.nccn.org). We included these women as in prior 
analyses [19] because findings were adjusted for comorbidity. Hormonal therapy was 
generally considered guideline-concordant if administered for ER+ and/or PR+ tumors and 
not for ER−/PR− tumors (www.nccn.org).
Diabetes and other comorbidity information were collected using the Adult Comorbidity 
Evaluation-27 index (ACE-27) [20], a comorbidity index specific to cancer patients. The 
ACE-27 includes 26 comorbid conditions, with three levels of severity for most. The 
ACE-27 defines mild diabetes as adult-onset diabetes well-controlled with oral agents and 
moderate diabetes as adult-onset disease poorly controlled using oral agents or 
uncomplicated insulin-dependent diabetes. Poor control is defined as elevated glucose levels 
while using oral agents, or frequent visits for monitoring glucose and treatment 
modifications. Severe diabetes is defined as involving end-organ impairment or recent 
hospitalization for diabetic ketoacidosis [20]. Because of small numbers of severe diabetes 
cases, we categorized severe diabetes with the moderate group.
Explanatory variables (covariates) included age, race/ethnicity, education and income 
(census tract-level), insurance, registry, body mass index (BMI, from medical records), and 
comorbidity score (from the ACE-27 excluding diabetes, obesity, and index breast cancers). 
For tumor characteristics, we included AJCC stage, tumor size, nodal status, histology, 
grade, ER/PR status, and human epidermal growth factor receptor 2 (HER2) status.
We presented frequencies and weighted proportions and used Rao-Scott Chi square tests 
[21] to examine the associations of diabetes with sociodemographic and tumor 
characteristics, and guideline-concordant treatment. Multivariable logistic regression models 
were employed to examine the independent association of diabetes with guideline-
concordant treatment after adjusting for covariates. Separate models were created for each 
treatment type (locoregional, adjuvant chemotherapy, and hormonal therapy). In all models, 
age was treated as a continuous variable and transformed using restricted cubic spline 
functions to allow for non-linearity. We included an interaction term for age and diabetes to 
examine whether the association of diabetes with treatment varied by age. Non-significant 
interaction terms (p ≥ 0.05) were removed from models. To examine the effect of covariates 
on the association of diabetes with treatment, we ran four models for each treatment 
outcome to sequentially adjust for covariate groups (first age, then additionally adjusting for 
comorbidity and BMI, then adding tumor characteristics, and finally sociodemographic 
factors). The influence of individual covariates was determined by examining the change in 
diabetes coefficients.
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We imputed missing information for education (n = 19), income (n = 19), insurance (n = 
233), BMI (n = 1,495), and grade (n = 399) using multiple imputation (ten imputations) via 
the aregImpute function from the Hmisc package (version 3.10-1.1) in R, which performed 
multiple imputation using predictive mean matching. ER/PR status was unknown for both 
receptors for 386 women and for one receptor for 57 women; HER2 status was unknown for 
1,204 women. For treatment analyses, we imputed unknown information for ER/PR and 
HER2 except in cases where medical records indicated that the test was not done [neither 
ER nor PR test done (n = 129); HER2 not done (n = 828)]. This was because treating 
physicians would not have had this information at the point of decision. All descriptive 
analyses were performed using SAS version 9.3 and SUDAAN version 11.0.0 to account for 
the complex sample design and allow for weighted estimates. Statistical modeling was 
performed using the rms package (version 4.1-0) and survey package (version 3.28-2) in R 
(version 3.0.2).
Results
Approximately 10 % of women had diabetes, with 8.6 % having mild diabetes and <2 % 
having moderate/severe diabetes (Table 1). About one quarter of women were younger than 
50 years with a similar proportion 70 years or older. Most women were non-Hispanic white 
with 14 % black, 6 % Hispanic, <4 % Asian or American Indian/Alaska Native (AIAN). 
Almost one-third of women resided in census tracts with low education levels and almost 
one-fifth resided in low income areas. More than 60 % were privately insured although more 
than one-third had only public insurance. Almost half of women had no comorbid 
conditions; 9 % had moderate to severe comorbidity. Stage I disease was present in 
approximately half of women, with 14 % stage III. Two-thirds of cancers were node 
negative, less than one quarter were ER−/PR− and 16.5 % were HER2+. Almost 40 % were 
poorly differentiated or undifferentiated.
Greater diabetes prevalence and severity was associated with age, race/ethnicity, education, 
poverty, insurance, BMI, and comorbidity (Table 2). The proportion of women with 
moderate/severe diabetes was greatest among women who were age ≥70, black, residents of 
census tracts with low education or low income or who were publicly insured, and who had 
BMI ≥40 or severe comorbidity.
In unadjusted analyses (Table 3), compared with women with no or mild diabetes, women 
with moderate/severe diabetes were more likely to have stage III disease (19 % vs. 12–14 %, 
p = 0.056), and tumor size ≥5 cm (13 % vs. 5–7 %, p = 0.044). Other associations of 
diabetes with tumor characteristics were not significant.
Before adjusting for covariates, increasing diabetes severity was significantly associated 
with less frequent receipt of guideline-concordant locoregional treatment (p = 0.030 and 
adjuvant chemotherapy (p < 0.0001; Table 4). For locoregional treatment, most women 
received guideline-concordant treatment regardless of diabetes severity (79–86 %). 
However, guideline concordance declined with increasing severity. Among women aged 40–
64, approximately 30 % of those with moderate/severe diabetes did not receive guideline-
concordant locoregional care, a significant difference compared with non-diabetic women 
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71.0 % (95 % CI 52.1–84.6 %) versus 89.4 % (95 % CI 88.0–90.6 %, not shown). For 
adjuvant chemotherapy, differences by diabetes severity were greater, with more than 40 % 
of diabetic women not receiving guideline-concordant care, including 50 % of women with 
moderate/severe diabetes. Guideline concordance for hormonal therapy was about the same 
across diabetes severity groups.
After adjusting for all factors, there was a significant interaction of diabetes severity with 
age for locoregional treatment (p = 0.001; Fig. 2; Table 4). Compared with similarly aged 
women without diabetes, receipt of guideline-concordant locoregional treatment was 
significantly reduced for women in their late fifties through mid-sixties with mild diabetes, 
and was considerably lower for women between their late forties and early sixties with 
moderate/severe diabetes. For example, compared with no diabetes the odds ratio for 
receiving guideline-concordant locoregional treatment for a 60-year-old woman with mild 
diabetes was 0.59 (95 % CI 0.38–0.92) and with moderate/severe diabetes was 0.26 (95 % 
CI 0.10–0.68) (not shown). Guideline concordance was higher among women in their mid-
seventies to early eighties with moderate/severe diabetes.
Diabetes severity was not associated with guideline-concordant hormonal treatment after 
adjusting for covariates (Table 4), and the diabetes by age interaction was not significant (p 
= 0.130). For adjuvant chemotherapy, unadjusted differences by diabetes severity were 
largely explained by age, which was the greatest confounder of diabetes severity (Table 4; 
Fig. 3). After further adjusting for comorbidity and BMI, the association was no longer 
significant. When tumor characteristics and sociodemographic factors were added, 
differences by diabetes severity regained significance (p = 0.042), with women with 
moderate/severe diabetes less likely to receive guideline-concordant care than non-diabetic 
women. Findings from the fully adjusted model were almost identical to those adjusted only 
for age. The interaction between diabetes and age was not significant (p = 0.061).
Discussion
Diabetes has been associated with lower breast cancer survival and greater breast cancer 
mortality [9–14], and some have postulated that differences in cancer treatment may 
contribute to such potentially worse outcomes [10, 15]. After adjusting for 
sociodemographic factors, comorbidity, BMI, and tumor characteristics, findings from this 
large population-based sample suggest that some diabetic women were less likely to receive 
guideline-concordant breast cancer treatment than non-diabetic women. This includes 
women with moderate/severe diabetes, who were less likely to receive both guideline-
concordant locoregional treatment (among those in their late forties to early sixties) and 
adjuvant chemotherapy. Women with mild diabetes were also less likely to receive 
guideline-concordant locoregional care among those in their late fifties to mid-sixties. For 
both locoregional treatment and chemotherapy, lower guideline concordance was not 
explained by increased comorbidity burden.
Others have also reported significant interaction between age and diabetes on breast cancer 
treatment. In a Dutch population, van de Poll-Franse [22] reported that diabetic women 
younger than 65 were more likely to receive surgery and hormonal therapy and less likely to 
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receive chemotherapy than non-diabetic women, while older diabetic women were less 
likely to receive radiotherapy. Lower radiotherapy use among older diabetic women in their 
sample was reported to be related to less frequent receipt of breast-conserving surgery [22], 
and thus may not have reflected inappropriate care. Our findings suggest that after 
controlling for other factors, older diabetic women were not less likely to receive guideline-
concordant locoregional treatment overall. In fact, among women in their mid-seventies to 
early eighties moderate/severe diabetes was associated with increased guideline concordance 
for locoregional treatment. Reasons for this are uncertain. Others have suggested that older 
women with diabetes may be more likely to receive mastectomy than breast-conserving 
surgery [10, 22–24], which for many may equate to guideline concordance. Among women 
who do receive breast-conserving surgery, older women have been shown to be less likely to 
receive radiotherapy than younger women [17, 24]. Taken together, these factors may 
contribute to the higher guideline concordance among some older women with moderate/
severe diabetes in our sample.
Our finding of less frequent receipt of guideline-concordant locoregional treatment among 
younger diabetic women, as in Fig. 2, may have implications for recurrence risk and other 
outcomes [25, 26]. For example, failure to receive recommended radiation leads to higher 
rates of recurrence [24–26] and breast cancer mortality [25, 27], and possibly all-cause 
mortality [26–28]. Lower guideline concordance may reflect contraindications to or 
perceived risks of treatment. For younger women, more severe diabetes may have 
heightened concerns about potential adverse effects of surgery or radiation. For older 
women, rates of guideline-concordant care declined with age regardless of diabetes severity. 
Others have also reported lower rates of guideline-concordant locoregional treatment with 
older age [17, 24]. Surgical and radiation risks may be a concern in this age group [24]. 
Furthermore, potentially small reductions in recurrence with radiation among older women 
[29] may lead to less frequent use [17, 24], as noted above, and consequently less frequent 
guideline concordance. Alternatively, reduced performance status may explain some 
differences by age [30].
Appropriate use of adjuvant chemotherapy improves survival [18, 31]. The inverse 
association between receipt of guideline-concordant adjuvant chemotherapy and diabetes 
severity was significant in this study, with women with moderate/severe disease tending 
toward less frequent guideline-concordant care. Others have reported less frequent receipt of 
chemotherapy among diabetic patients, but did not examine guideline concordance or 
include diabetes severity [10, 22]. Our findings suggest that compared with women without 
diabetes, guideline concordance may not be lower for women with mild diabetes, who 
represent most diabetic women in our sample (84 %). This in turn raises questions regarding 
whether differences in guideline-concordant chemotherapy as a contributing factor to 
potentially worse breast cancer outcomes among diabetic patients [9–11] might be limited to 
those with more severe diabetes. Other factors might contribute to potentially worse 
outcomes for diabetic women [9–11]. Different rates of chemotherapy complications among 
diabetic patients [10] might lead to differences in completing recommended treatments, 
which could impact outcomes. Furthermore, reduced doses or different regimens may 
contribute [32]. Obesity could also be a factor given its associations with diabetes, dose 
intensity, and worse cancer outcomes [33].
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The unadjusted association between diabetes severity and guideline-concordant adjuvant 
chemotherapy was largely confounded by age. Diabetes prevalence and severity increased 
with age, and as our findings indicate, older women are less likely to receive guideline-
concordant breast cancer care than younger women, consistent with previous evidence [30, 
34–37]. Less is known about the effectiveness of adjuvant chemotherapy among women over 
age 70 and NCCN guidelines state that evidence was insufficient to make recommendations 
for that age group (www.nccn.org). Instead they advised individualizing chemotherapy 
decisions according to a woman’s comorbidities. Our findings were adjusted for 
comorbidity, suggesting that differences in chemotherapy administration among older 
women were not driven by greater comorbidity burden, consistent with other findings [30, 
38]. However, specific individual comorbid conditions more common among older women, 
such as heart failure or dementia, may have influenced decisions regarding chemotherapy for 
this group, as may concerns about increased vulnerability to chemotherapy-induced toxicity 
[17, 39, 40] or performance status [30].
Our study included a large population-based sample from seven states, with routine cancer 
registry data enhanced by medical record review. This enabled us to incorporate detailed 
cancer treatment and comorbidity information with cancer registry information. We 
examined whether the care received by each woman was concordant with guidelines, and 
our data included information about diabetes severity not available in other studies [10, 22, 
41]. We also included women younger than 55 years old unlike other studies of treatment 
differences [10, 17]. Despite these strengths, several factors should be considered. First, 
because of small numbers of women with severe diabetes, we combined moderate and 
severe diabetes, which may have obscured associations of diabetes severity with treatment. 
Second, we did not examine chemotherapy regimens. It is unknown whether diabetic 
patients received less aggressive [10] or non-recommended regimens (http://www.nccn.org), 
or reduced doses or cycles of chemotherapy [10, 22, 32]. Third, according to the ACE27, 
adult-onset diabetes controlled by diet alone is not coded [20]. Therefore, these women 
would have been combined with the no diabetes group. This might bias toward the null, 
although diabetic women well-controlled without medication may be most likely to be 
treated the same as non-diabetic women. Fourth, we excluded women for whom guideline 
concordance could not be determined. Finally, data are from seven states, which may affect 
generalizability.
In summary, among women with stage I–III breast cancer, some diabetic women were less 
likely to receive guideline-concordant care than non-diabetic women. Mild and moderate/
severe diabetes were associated with less frequent receipt of guideline-concordant 
locoregional treatment for many women younger than 65 years old. Moderate/severe 
diabetes was also associated with a lower likelihood of receiving guideline-concordant 
adjuvant chemotherapy. For these groups of women, lower rates of guideline-concordant 
cancer treatment may contribute to potentially worse breast cancer outcomes.
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Fig. 1. 
Flow chart of exclusions by analysis
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Fig. 2. 
Adjusted relationship between age and guideline-concordant locoregional treatment by 
diabetes severity
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Fig. 3. 
Adjusted relationship between age and guideline-concordant adjuvant chemotherapy
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Table 1
Sociodemographic, health, and tumor characteristics of women with stage I–III breast cancer, National 
Program of Cancer Registries Patterns of Care for Breast and Prostate Cancer Study (n = 6,912)
N Weighted %
Diabetesa
 None 6,060 89.8
 Any diabetes 852 10.2
  Mild diabetes 712 8.6
  Moderate/severe diabetes 140 1.6
Age at diagnosis
 <50 2,012 26.6
 50–59 1,774 25.8
 60–69 1,419 21.2
 70+ 1,707 26.4
Race/ethnicity
 Non-Hispanic white 3,995 76.6
 Non-Hispanic black 1,877 13.7
 Hispanic 600 6.0
 Asian 382 3.4
 AIAN 58 0.3
Census tract educationb
 Low 2,687 31.0
 High 4,206 69.0
Census tract incomec
 Low 1,730 17.4
 High 5,163 82.6
Insurance
 Private 3,993 63.3
 Public only 2,480 34.5
 None 206 2.2
Registryd
 A 414 9.3
 B 689 10.6
 C 1,348 9.5
 D 1,289 23.7
 E 791 17.8
 F 785 11.5
 G 1,596 17.7
BMI
 <25 1,716 34.3
 25 to <30 1,609 30.3
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N Weighted %
 30 to <40 1,700 29.6
 40+ 392 5.9
Comorbidity scoree
 None 3,314 48.0
 Minor 2,987 42.7
 Moderate 432 6.8
 Severe 179 2.5
Cancer Stage
 I 3,246 49.2
 II 2,644 37.2
 III 1,022 13.6
Tumor size (cm)
 T0/<1.0 1,252 19.6
 1.0 to <3.0 4,003 59.3
 3.0 to <5.0 1,031 14.6
 ≥5.0 537 6.5
Nodal Status
 N0 4,475 66.9
 N1mi, 0.2–2.0 mm 273 3.9
 N1, >2.0 mm 1,358 18.4
 N2 523 7.1
 N3 281 3.7
Histology type
 Tubular/colloid 254 3.8
 Ductal/lobular/mixed 6,392 92.7
 Other 266 3.5
ER/PR status
 ER+ and/or PR+ 4,886 75.6
 ER−/PR− 1,640 22.6
 Neither test done 136 1.9
HER2 status
 Positive 1,061 16.5
 Negative 4,354 67.0
 Equivocal 293 4.1
 Test not done 828 12.4
Grade
 Well differentiated 1,214 20.4
 Moderately differentiated 2,647 41.2
 Poorly/undifferentiated 2,652 38.4
aAs determined by ACE-27 index
b
Low/high education defined as ≥25 % versus <25 % of census tract residents with less than high school education
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c
Low/high income defined as ≥20 % versus <20 % of census tract residents below the federal poverty level
d
Participating registries include Georgia, North Carolina, Kentucky, Louisiana, Wisconsin, Minnesota, and California
eAs determined by ACE-27 index, excluding diabetes, obesity, and index breast cancer
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